We Need New Cancer Biomarkers
Since the end of 2019, the global health emergency related to the spread of Sars-Cov-2 has attracted the interest of researchers, clinicians, pharmaceutical companies, and the media from all over the world. To date, interest has not diminished due to the spread of multiple variants, typical of RNA viruses. Probably this virus will accompany us from now on and it will not be possible to eradicate it as it was done in the past with smallpox and as we have not been able to do so far with the Human Immunodeficiency Virus (HIV). We will have to live with it as it already happens with many other virus species widely spread around the world. Without diminishing the importance of this highly current issue, it must be said that it has distracted not a few economic resources, human resources, time, and energy in the search and early diagnosis of other diseases, much more insidious and lethal as they are chronic-degenerative especially cancer. As is well-known, cancer is a complex, insidious, multifactorial, chronic-degenerative disease and today some cancers, such as lung cancer, are still among the top ten causes of death: in sixth place in the global ranking and at third place in Europe.....